-
How to invest in biotechnology: the healthcare sector’s high-growth area
Cover Story Dr Mike Tubbs provides an overview of this thriving industry, whose latest triumphs include the Covid-19 vaccines. He examines the best investment strategies and highlights his favourite picks.
Cover Story -
AstraZeneca’s shareholders rebel over pay
News Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
News -
Vaccine patents: a bitter pill for drug companies
News The US has suggested waiving drug companies’ vaccine patents to hasten the defeat of Covid-19, sending their share prices down.
News -
Activist investor Elliott takes takes a stake in Glaxo
News Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.
News -
The unscientific criticism of AstraZeneca could do lasting damage
News Several European countries have suspended their use of AstraZeneca's Covid vaccine – for no good scientific reason. Matthew Partridge reports.
News -
Johnson & Johnson vaccine approval is another shot in the arm for the world
News Johnson & Johnson’s vaccine has been approved in the US, a sign that the world is making solid progress against Covid-19. Matthew Partridge reports
News -
How to invest in the latest developments in hearing technology
Cover Story Traditionally dismissed as a relative backwater, this branch of medicine is about to move into the limelight thanks to ageing populations and major breakthroughs, says Matthew Partridge
Cover Story -
Vanquishing the virus: the race to make vaccines for Covid-19
Cover Story The extraordinarily rapid development of effective treatments against the coronavirus is a triumph of biotechnology, says Dr Mike Tubbs. He reviews the story and explains what it means for investors.
Cover Story -
Vexing vaccine delays hit drug firms
News AstraZeneca and Pfizer are being attacked by the EU over what it claims are delays in delivering the Covid vaccine.
News
